Itraconazolo Sandoz

Itraconazole, the active ingredient in Itraconazolo Sandoz, is a triazole antifungal presented as an oral tablet formulation for oral use. It is indicated for the treatment of a range of superficial and systemic mycoses caused by susceptible fungi in adult patients, including dermatophyte infections, onychomycosis, and invasive candidiasis.

GNH USA supplies Itraconazolo Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to manage fungal infections across several disease categories.

Dermatophytosis (ringworm): reduces fungal growth and clears skin lesions. Onychomycosis (nail fungus): promotes regrowth of healthy nail tissue. Systemic mycoses such as blastomycosis, histoplasmosis, and sporotrichosis: eradicates invasive fungal infection. Chronic pulmonary aspergillosis: controls fungal burden and improves respiratory symptoms.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea - Headache - Abdominal pain or discomfort - Rash or mild skin irritation - Taste disturbance (dysgeusia) - Diarrhea

Serious or Rare Side Effects: - Hepatotoxicity, including severe hepatitis - Severe skin reactions such as Stevens‑Johnson syndrome - Congestive heart failure or worsening of existing heart failure - Significant electrolyte disturbances, especially hypokalemia - Visual disturbances or blurred vision

Before initiating therapy, consider the following safety measures.

Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. Drug interaction review: evaluate concomitant medications for CYP3A4 substrates or inhibitors. Cardiac assessment: avoid use in patients with known congestive heart failure. Pregnancy and lactation: prescribe only if potential benefit outweighs risk. Renal impairment: use with caution in severe renal dysfunction. Store at ambient temperature: keep in the original container, protect from moisture and light.

Itraconazole has several clinically relevant drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce itraconazole exposure. - Concomitant QT‑prolonging agents (e.g., quinidine, cisapride): increased risk of arrhythmia. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may cause itraconazole toxicity.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy. - Oral anticoagulants (warfarin): check INR more frequently. - Sulfonylurea hypoglycemics: observe for enhanced hypoglycemic effect.